Status:
UNKNOWN
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Conditions:
Renal Cell Carcinoma
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, is is mandatory to improve the r...
Detailed Description
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, is is mandatory to improve the r...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of metastatic melanoma, renal cell carcinoma, or hepatocarcinoma (Child´s stage A or B) not amenable of curative treatment. For patients with hepatocarcinoma, treatment after embolization is allowed
- Measurable disease
- ECOG 0, 1 or 2.
- Adequate renal, hepatic and bone marrow function
- Availability of tumor tissue, for maturing dendritic cells
Exclusion
- Clinically relevant diseases or infections.
- concurrent participation in other clinical trial or administration or other antitumoral treatment
- Concurrent cancer, with the exceptions allowed by the PI.
- Pregnant or breast feeding women
- immunosuppressant treatment
- known CNS metastasis
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00610389
Start Date
February 1 2008
End Date
December 1 2010
Last Update
May 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Department. Clinica Universitaria de Navarra
Pamplona, Navarre, Spain, 31008